Clinical Features and Therapeutic Targets for Myeloproliferative Neoplasms

SELF STUDY / ENDURING - ESTIMATED TIME TO COMPLETE ACTIVITY: 75 Minutes

Overview

Many myeloproliferative neoplasms (MPNs) share similar symptoms, but it is important to distinguish, diagnose, and treat MPNs appropriately. An expert faculty will share strategies for identifying MPNs and their associated recommended management. Participants will gain a better understanding of novel therapies and evidence-based treatment plans for those diagnosed with MPN by walking through realistic clinical scenarios during this activity.

Target Audience

This CME initiative was designed for oncologists, surgeons, radiation oncologists, NPs, PAs, pharmacists, nurses, and other healthcare professionals involved in the treatment of patients with cancer.

Learning Objectives

1. Review the clinical features of myeloproliferative neoplasms with a focus on chronic myeloid leukemia, chronic eosinophilic leukemia, and primary myelofibrosis
2. Identify novel management approaches for the myeloproliferative neoplasms discussed integrating genetics, patient-specific factors, and new therapies
3. Describe evidence-based treatment plans for patients diagnosed with myeloproliferative neoplasms using clinical scenarios

Course summary
Available credit: 
  • 1.00 AMA PRA Category 1 Credit™
    Horizon CME designates this Enduring activity for a maximum of 1.00 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
  • 1.00 ANCC
    This activity has been planned and implemented in accordance with the accreditation requirements and policies of the American Nurses Credentialing Center’s Commission on Accreditation through the joint providership of the Nurse Practitioner Healthcare Foundation and Horizon CME. The Nurse Practitioner Healthcare Foundation is accredited as a provider of nursing continuing professional development by the American Nurses Credentialing Center’s Commission on Accreditation. NPHF is awarding the contact hours and is responsible for adherence to the ANCC criteria. This course is approved by the Nurse Practitioner Healthcare Foundation, California Board of Registered Nursing, CEP# 16441. Upon completion, NPs and RNs will be awarded up to 1.00 credit.
Course opens: 
09/15/2023
Course expires: 
09/15/2024
Cost:
$0.00
Rating: 
0

Faculty

Gary Schiller, MD

Dr.Schiller is the Director of the Hematological Malignancy/ Stem Cell Transplant Program at the David Geffen School of Medicine at UCLA, supervising 200 transplants per year in 2017 and 2018.  He has extensive clinical research experience, having conducted many investigator-initiated and multicenter trials, mostly in Hematologic Malignancies as well as Blood and Marrow Transplantation.  He is immediate past Chair of the Faculty Executive Committee for the School of Medicine at UCLA. He is an author of over 170 publications and 320 abstracts. He has mentored residents, medical students, and fellows for more than 25 years.  He has also served as a member and Chair of the Committee on Training for the American Society of Hematology and worked with its Trainee Council developing programs for the national meeting of the Society and curriculum for its Trainee Day and is presently Chair of the ASH Foundation committee.

Dr.Schiller has an outstanding track record in clinical research, teaching, and mentoring and was co-investigator on Alternative Training grant for Bone Marrow Failure syndromes.  He also has extensive experience outside of medicine, with nonprofit, charitable institutions.  He has served on the Board of Trustees of Wilshire Boulevard Temple, and was Chairman of the Los Angeles Museum of the Holocaust. .Dr.Schiller has over 25 years of experience in the diagnosis and management of adults with Hematologic Malignancies and those undergoing allogeneic stem cell transplantation for non-malignant disorders including sickle cell disease.

 

Disclosures:

In accordance with the ACCME Standards for Integrity and Independence in Accredited Continuing Education, Horizon CME (HCME) ensures that continuing education activities are balanced, independent, objective, and scientifically rigorous. 

All persons in a position to influence the content of an accredited continuing education activity provided by Horizon CME are required to disclose to HCME any relevant financial relationships with ineligible companies within the past 24 months. All reported relevant financial relationships have been mitigated by Horizon CME.

Gary Schiller, MD  had Consultant Fee with BMS, Curios and Daiichi. He has Advisory Board with Agios, Gamida, Gilead, Incyte, Amgen, BMS, Novartis, Ono Pharma, AVM Biotech, GSK, and AZ. He has stock in Amgen, BMS and Janssen/J&J. He has other financial or non-financial interest with AbbVie, Actinium, Actuate, Agios, Arog, Astellas, AltruBio, BMS/Celgene, Biopath, BioMea, BioSight, Cellularity, Celator, Constellation, Cogent, Cellectis, Daiichi-Sankyo, Deciphera, Delta-Fly, Fate, Forma, Fujifilm, Gamida, Genetech-Roche, Glycomimetics, Geron, Incyte, Karyopharm, Kiadis, Kite/Gilead, Kronos Bio Kura, Janssen, Immunogene, Loxo, Marker, Mateon, Onconova, Pfizer, PrECOG, Regimmune, Samus, Sangamo, Sellas, Stemline, Syros, Takeda, Tolero, Trovagene, Amgen, Jazz, Orca, Ono-UK and Novartis, during the past 24 months.*

Available Credit

  • 1.00 AMA PRA Category 1 Credit™
    Horizon CME designates this Enduring activity for a maximum of 1.00 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
  • 1.00 ANCC
    This activity has been planned and implemented in accordance with the accreditation requirements and policies of the American Nurses Credentialing Center’s Commission on Accreditation through the joint providership of the Nurse Practitioner Healthcare Foundation and Horizon CME. The Nurse Practitioner Healthcare Foundation is accredited as a provider of nursing continuing professional development by the American Nurses Credentialing Center’s Commission on Accreditation. NPHF is awarding the contact hours and is responsible for adherence to the ANCC criteria. This course is approved by the Nurse Practitioner Healthcare Foundation, California Board of Registered Nursing, CEP# 16441. Upon completion, NPs and RNs will be awarded up to 1.00 credit.

Price

Cost:
$0.00
Please login or register to take this course.

There are no fees for participating and receiving CME credit for this enduring activity. To receive CME credit participants must:

  1. Read the CME/CE information and faculty disclosures.
  2. Participate in the online activity.
  3. Complete the post-test and score a minimum of 70%
  4. Submit the evaluation form

DISCLAIMER:

This activity is designed for educational purposes. Participants have a responsibility to utilize this information to enhance their professional development to improve patient outcomes. Conclusions drawn by the participants should be derived from careful consideration of all available scientific information. The participant should use his/her clinical judgment, knowledge, experience, and diagnostic decision-making before applying any information, whether provided here or by others, for any professional use.

Required Hardware/software

Access to the internet is required.

Supported Browsers:

Internet Explorer 8.0+ for Windows 2003, Vista, XP, Windows 7, Windows 8.1 and above

Google Chrome 28.0+ for Windows, Mac OS, or Linux

Mozilla Firefox 23.0+ for Windows, Mac OS, or Linux

Safari 6.0+ for Mac OSX 10.7 and above

 

Supported Phones & Tablets:

 Android 4.0.3 and above

iPhone/iPad with iOS 6.1 or above